- Home
- BTE vs HRMY Comparison
BTE vs HRMY Comparison
Compare BTE & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTE
- HRMY
- Stock Information
- Founded
- BTE 1993
- HRMY 2017
- Country
- BTE Canada
- HRMY United States
- Employees
- BTE N/A
- HRMY N/A
- Industry
- BTE Meat/Poultry/Fish
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- BTE Consumer Staples
- HRMY Health Care
- Exchange
- BTE Nasdaq
- HRMY Nasdaq
- Market Cap
- BTE 1.8B
- HRMY 1.5B
- IPO Year
- BTE N/A
- HRMY 2020
- Fundamental
- Price
- BTE $3.00
- HRMY $34.02
- Analyst Decision
- BTE
- HRMY Strong Buy
- Analyst Count
- BTE 0
- HRMY 9
- Target Price
- BTE N/A
- HRMY $50.44
- AVG Volume (30 Days)
- BTE 22.8M
- HRMY 928.1K
- Earning Date
- BTE 10-30-2025
- HRMY 11-04-2025
- Dividend Yield
- BTE 2.13%
- HRMY N/A
- EPS Growth
- BTE N/A
- HRMY 50.44
- EPS
- BTE 0.20
- HRMY 3.17
- Revenue
- BTE $2,194,819,404.00
- HRMY $825,944,000.00
- Revenue This Year
- BTE N/A
- HRMY $20.68
- Revenue Next Year
- BTE N/A
- HRMY $15.93
- P/E Ratio
- BTE $15.37
- HRMY $10.72
- Revenue Growth
- BTE N/A
- HRMY 21.13
- 52 Week Low
- BTE $1.36
- HRMY $25.52
- 52 Week High
- BTE $3.25
- HRMY $40.93
- Technical
- Relative Strength Index (RSI)
- BTE 69.17
- HRMY 72.12
- Support Level
- BTE $2.27
- HRMY $33.39
- Resistance Level
- BTE $3.25
- HRMY $34.35
- Average True Range (ATR)
- BTE 0.13
- HRMY 1.23
- MACD
- BTE 0.08
- HRMY 0.53
- Stochastic Oscillator
- BTE 75.98
- HRMY 89.22
About BTE Baytex Energy Corp
Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.